Hetty Carraway, MD
Hematology & Oncology · Chagrin Falls, OHNPI 1457319717
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 22.5%. Reporting peaked in 2020 at $96,512 and has fallen 64.2% since, to $34,560 in 2025. Among hematology & oncology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $1236.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$94K
- Jazz Pharmaceuticals Inc.$42K
- Agios Pharmaceuticals, Inc.$41K
- E.r. Squibb & Sons, L.L.C.$38K
- Daiichi Sankyo Inc.$32K
- Novartis$31K
- plus $138K from 15 others
Across 111 payments — averaging $12,512 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$351K
- AbbVie$313K
- Takeda Pharmaceuticals U.S.A., Inc.$186K
- Bristol Myers Squibb$160K
- Rigel Pharmaceuticals, Inc.$115K
- Novartis$107K
- plus $157K from 6 others
What the payments were for
- Consulting fees$204,51449%
- Speaking & faculty fees$184,48344%
- Travel & lodging$19,3315%
- Food & beverage$7,1512%
- Education$1490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 60 | $93,535 |
| Jazz Pharmaceuticals Inc. | 36 | $42,308 |
| Agios Pharmaceuticals, Inc. | 58 | $40,993 |
| E.r. Squibb & Sons, L.L.C. | 22 | $38,033 |
| Daiichi Sankyo Inc. | 40 | $31,502 |
| Novartis | 19 | $31,071 |
| AbbVie | 36 | $25,466 |
| Otsuka Pharmaceutical Co., Ltd. | 2 | $24,340 |
| Stemline Therapeutics Inc. | 13 | $21,458 |
| Servier Pharmaceuticals LLC | 8 | $14,565 |
| Genentech USA, Inc. | 9 | $11,816 |
| Sanofi | 5 | $10,361 |
| Gilead | 3 | $6,315 |
| Rigel Pharmaceuticals, Inc. | 6 | $5,143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $4,840 |
| Geron Corporation | 2 | $4,823 |
| AstraZeneca | 5 | $2,908 |
| Syndax Pharmaceuticals, Inc. | 4 | $2,572 |
| Boehringer Ingelheim International GmbH | 1 | $1,692 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $1,601 |
| Astellas Pharma US Inc | 3 | $284 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$415,627 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 17 | $567,260 |
| RydaptMidostaurin | 11 | $234,522 |
| RevlimidLenalidomide | 12 | $211,233 |
| TasignaNilotinib Hcl | 13 | $127,451 |
| VenclextaVenetoclax | 24 | $20,612 |
| Acyclovir | 69 | $1,024 |
| Ondansetron Hcl | 14 | $226 |
| Levofloxacin | 21 | $110 |
| Prednisone | 13 | $99 |
| Allopurinol | 33 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Servier Pharmaceuticals LLCTibsovo | $14,565 | $567,26017 claims |
| NovartisRydapt, Tasigna | $31,071 | $361,97424 claims |
| Bristol Myers SquibbRevlimid | $93,535 | $211,23312 claims |
| AbbVieVenclexta | $25,466 | $20,61224 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Chagrin Falls
- Hillard LazarusCleveland$2M
- Kasra KaramlouSandusky$1.8M
- David WaterhouseCincinnati$1.3M
- Taral PatelColumbus$888K
- Tarek ChidiacColumbus$765K
- Saulius GirniusMontgomery$707K
- Ronald BukowskiCleveland$594K
- Balazs HalmosCleveland$568K
- Jorge GarciaCleveland$513K
- Alejandro CalvoKettering$463K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.